Design And Characterization Of Ceritinib Self- Nanoemulsifying Drug Delivery Systems (SNEDDS)
Abstract
The main objective of the current study was to develop ceritinib SNEDDS for the improvement of solubility, permeability and drug release. Solubility of ceritinib was studied in various oils, surfactants and co-surfactants and based on its maximum solubility an oil, surfactant and co-surfactant were chosen (captex355,tergitol and propylene glycol) and mixed in varying ratios , the ratios with no phase separation, maximum transmittance and clear in appearance were identified and used for plotting pseudo tertiary phase diagram. Fifteen SNEDDS formulations were selected from miscible regions of pseudo ternary phase diagram subjected to thermodynamic stability testing. Formulations that passed stability testing were evaluated for % transmission, drug content and in vitro drug release analysis. The final optimized formulation was analysed for particle size, Z average and zeta potential followed by FTIR and SEM analysis. Formulation F13 with maximum drug release of 98.9% in 60 minutes that is higher than 48 % of pure drug is considered the optimised formulation. The particle size, Z average and zeta potential of the ceritinib SNEDDS formulation F13 were 144 nm, 132 nm and -7.2 mV respectively. The FTIR and SEM studies do not indicate any drug excipient interaction and confirm uniform drug distribution. The formulation subjected to accelerated stability study is proved to be stable over a period of six months. The results indicate ceritinib SNEDDS formulations can be designed in order to enhance the solubility of ceritinib and thereby increase in its absorption rate and drug release.
Keywords:
Ceritinib, SNEDDS, Solubility, anaplastic lymphoma kinase (ALK), Zeta potentialDOI
https://doi.org/10.25004/IJPSDR.2021.130316References
Reck M, Popat S, Reinmuth N. Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(3):27–39
Khozin S, Blumenthal GM, Zhang L. FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer. Clin Cancer Res. 2015;21(11):2436– 2439.
Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311: 899–909.
Melosky B, Agulnik J, Albadine R. Canadian consensus: inhibition of ALK-positive tumours in advanced non-small-cell lung cancer. Curr Oncol. 2016;23(3):196–200
Chow LQM, Barlesi F, Bertino EM. Ceritinib in ALK+ NSCLC metastatic to brain and/or leptomeninges: the ASCEND-7 study. In the proceedings of 16th World Conference on Lung Cancer, 2015.
Li B, Harich K, Wegiel L, Taylor LS, Edgar KJ. Stability and solubility en- hancement of ellagic acid in cellulose ester solid dispersions. Carbohydr Polym. 2013;92:1443–1450.
Wanga L, Donga D, Chena J, Eastoeb J, Li X. Design and optimization of a new self-nanoemulsifying drug delivery system. J. Colloid Interface Sci. 2009;330 (2) : 443–448.
Hosseini MH, Alizadeh N, Khanchi AR. Effect of menthol as solid cosolvent on the solubility enhancement of clozapine and lamorigine in supercritical CO2. J. Supercrit. Fluids. 2010;55:14–22.
Ramanaiah CF, Ravi T.In Situ Metastable Form: A Route for the Generation of Hydrate and Anhydrous Forms of Ceritinib. Cryst. Growth Des. 2017; 17:6341–6352.
Gaddam Suvarsha. Development and optimization of solid lipid nanoparticle formulation for enhanced solubility of ceritinib using box–behnken design.AJP;2020:14(1).
Ghai D, Sinha VR. Nano-emulsions as self-emulsified drug delivery carriers for enhanced permeability of the poorly water-soluble selective β1-adrenorecep- tor blocker Talinolol, Nanomedicine. Nanotechnol Biol Med. 2011;5:618–626.
Abdalla A, Klein S, Mader K. A new self-emulsifying drug delivery system (SEDDS) for poorly soluble drugs: characterization, dissolution, in vitro digestion and incorporation into solid pellets,. Eur J Pharm Sci. 2008;35:457–464.
XiongweiHua, Chen Linc, DingxiongChenc, Jing Zhanga, ZhihongLiua, Wei Wub, HongtaoSonga, Sirolimus. solid self-microemulsifying pellet s: Formulat ion development , charac ter izat ion and bioavailability evaluation. International Journal of pharmaceutics. 2012;438:123-133.
Shantanu Bandyopadhyay, Katare, Bhupinder Singh. Optimized self nano-emulsifying systems of ezetimibe with enhanced bioavailability potential using long chain and medium chain triglycerides,colloids and surfaces. B: Biointerfaces 2012;100:50-61.
Published
Abstract Display: 516 
PDF Downloads: 554 
